Abusive Prescription of Psychostimulants: A Study of Two Cases

Pélissier-Alicot, Anne-Laure; Piercecchi-Marti, Marie-Dominique; Bartoli, Christophe; Kuhlmann, Erika; Coiffait, Philippe-Emmanuel; Sanvoisin, Alain; Giocanti, D.; Léonetti, Georges

doi:10.1111/j.1556-4029.2006.00078.x

Cited by 25 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…*Medication names were translated from Portuguese. †Many pill components listed would not be detected using our clinical laboratory's GC/MS technology addiction, 3,16 subarachnoid hemorrhage 17 and morphea. 18 Given the lack of monitoring of fenproporex use, it is certainly possible that other life-threatening events are currently occurring but unrecognized.…”

Section: Discussionmentioning

confidence: 99%

“…Initially developed to provide appetite suppression without stimulant effects, fenproporex has since been found to have addictive potential. 3 Fenproporex is rapidly converted in vivo into amphetamine 4 and the latter can be detected in urine for up to 60 hours after ingestion. 5 The United Nations has warned that overprescribing of amphetamine-based anorectics in South America could contribute to their international distribution.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Imported Fenproporex-based Diet Pills from Brazil: A Report of Two Cases

Cohen

2008

J GEN INTERN MED

View full text Add to dashboard Cite

Banned amphetamine-based anorectics are illicitly imported into the United States (US), but little is known regarding the harm these diet pills pose to US residents. A 26-year-old woman using imported diet pills presented with a two-year history of intermittent chest pains, palpitations, headaches and insomnia. Urine toxicology screen detected amphetamines and benzodiazepines. Fenproporex and chlordiazepoxide were detected in her pills. Her symptoms resolved after she stopped using diet pills. A 38-year-old man using imported diet pills presented after his occupational urine screen was significantly positive for amphetamine. Fenproporex and fluoxetine were detected in his pills. These cases illustrate the potential harm from imported prescription diet pills that combine fenproporex with benzodiazepines, antidepressants, diuretics, laxatives and other substances. Increasing physicians' awareness of imported diet pill use may improve care of patients suffering from the pills' many adverse effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Imported Fenproporex-based Diet Pills from Brazil: A Report of Two Cases

Cohen

2008

J GEN INTERN MED

View full text Add to dashboard Cite

show abstract

“…Zur Verlängerung der Wachperioden wird missbräuchlich Epinephrin, Coffein oder Modafinil (Vigil ® ), ein Medikament zur Behandlung der Narkolepsie als Lifestyle-Droge eingenommen, welches aber in Deutschland BTM-pflichtig ist [24]. Zu den häufigen Nebenwirkungen gehören zunehmende Nervosität und Kopfschmerzen.…”

Section: Sonstige Pharmakaunclassified

Lifestyle-Medikamente in der Medizin

Harth

Seikowski

Hermes

et al. 2008

Wien Med Wochenschr

View full text Add to dashboard Cite

Lifestyle drugs have become an important new group of medications, which are taken by healthy people to increase the individual well-being and quality of life. Nootropics, psychopharmaceuticals, hormones and "ecodrugs" are today the main groups. The wish for eternal youth, beauty and potency is central, and lifestyle medications are also requested to influence cosmetic findings, which are usually simply a result of the natural aging process. Lifestyle drugs seem to be harmless, but the physician must pay attention to possible abuse, side effects, risks and complications. Additionally, however, lifestyle drugs are also frequently used by patients suffering from emotional disorders such as somatoform disorders. Medicalization of physiological life is then expected to solve psychosocial problems, but without success. The use of lifestyle medications in somatoform disorders is contraindicated and psychotherapy or psychopharmacological treatment come first. With this overview article, we would like to make an update of new lifestyle drugs.

show abstract

“…The included studies comprised RCT (n=25) and case reports (n=6) (45)(46)(47)(48)(49)(50). Cohort and case-control studies that complied with our inclusion criteria were not identified.…”

Section: Study Characteristicsmentioning

confidence: 99%

Systematic Review and Meta-Analysis of The Efficacy And Safety Of Amfepramone and Mazindol As A Monotherapy for The Treatment of Obese or Overweight Patients

et al. 2017

View full text Add to dashboard Cite

The aim of this study was to evaluate efficacy and safety of amfepramone, fenproporex and mazindol as a monotherapy for the treatment of obese or overweight patients. A systematic review of primary studies was conducted, followed by a direct meta-analysis (random effect) and mixed treatment comparison. Medline and other databases were searched. Heterogeneity was explored through I 2 associated with a p-value. Of 739 identified publications, 25 were included in the meta-analysis. The global evaluation of Cochrane resulted in 19 studies with a high level of bias and six with unclear risk. Due to the lack of information in primary studies, direct meta-analyses were conducted only for amfepramone and mazindol. Compared to placebo, amfepramone resulted in higher weight loss in the short-term (o180 days; mean difference (MD) -1.281 kg; po0.05; I 2 : 0.0%; p=0.379) and long-term (X180 days; MD -6.518 kg; po0.05; I 2 : 0.0%; p=0.719). Only studies with long-term follow up reported efficacy in terms of abdominal circumference and 5-10% weight reduction. These results corroborated the finding that the efficacy of amfepramone is greater than that of placebo. Treatment with mazindol showed greater short-term weight loss than that with placebo (MD -1.721 kg; po0.05; I 2 : 0.9%; p=0.388). However, metabolic outcomes were poorly described, preventing a meta-analysis. A mixed treatment comparison corroborated the direct meta-analysis. Considering the high level of risk of bias and the absence of important published outcomes for anti-obesity therapy assessments, this study found that the evaluated drugs showed poor evidence of efficacy in the treatment of overweight and obese patients. Robust safety data were not identified to suggest changes in their regulatory status.

show abstract

Abusive Prescription of Psychostimulants: A Study of Two Cases

Cited by 25 publications

References 11 publications

Imported Fenproporex-based Diet Pills from Brazil: A Report of Two Cases

Imported Fenproporex-based Diet Pills from Brazil: A Report of Two Cases

Lifestyle-Medikamente in der Medizin

Systematic Review and Meta-Analysis of The Efficacy And Safety Of Amfepramone and Mazindol As A Monotherapy for The Treatment of Obese or Overweight Patients

Contact Info

Product

Resources

About